Trial Profile
A Continued Access Protocol to Provide Xolair (Omalizumab) to Subjects With Severe Allergic Asthma Who Have Received Xolair Treatment in a Previous Investigational Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Oct 2009
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors Genentech
- 31 Jul 2009 New trial record